Pharmacodynamics is the study of the biochemical and physiological effects of drugs on the body, including the mechanisms of action and the relationship between drug concentration and effect.

Atamyo Pharma Secures Approval from European Regulators to Commence Human Trials of ATA-200, Their Innovative Genetic Treatment for Limb-Girdle Muscular Dystrophy 2C/R5.

Gut-Derived Hormone Cholesin Found to Regulate Cholesterol Metabolism.

CinFina Pharma Reveals US Health Authority's Approval for Early-Stage Drug Trial and Commencement of Dosing in Initial Human Subjects for its Obesity Medication, CIN-110.

Pharmacokinetics (PK) is the study of how a drug moves through the body, which includes the processes of absorption, distribution, metabolism, and excretion.

Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare approved VYLOY™ (zolbetuximab), an anti-CLDN18.2 drug, for advanced and inoperable metastatic stomach cancer patients positive for CLDN18.2.

Curated Selection of the Latest Developments in the Field of New Drug Research and Development: A Quick Overview of Progress in New Drug R&D, Pharmaceutical Deals, and Cutting-Edge Technologies from This Week.

Initial enrollment of patients with stomach and esophageal cancer has begun for a second-stage mixed studies trial, utilizing Affibody's ABY-025 diagnostic tool for positron emission tomography.

On March 22, Johnson & Johnson announced FDA approval of OPSYNVI®, their new drug for treating WHO Group 1 PAH and class II-III PAH in adults. OPSYNVI® combines macitentan and tadalafil in a single tablet.

Corteria Pharmaceuticals has launched the first stage of clinical trials to assess the efficacy of their CRF2 activator, COR-1167, specifically targeting the progression of cardiac insufficiency.

Levocetirizine is a small, powerful drug that works as an H1 receptor antagonist to treat various allergies, including respiratory issues, dermatitis, and eczema.

Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10.